Novel targeted therapies for eosinophil-associated diseases and allergy.

Radonjic-Hoesli, Susanne; Valent, Peter; Klion, Amy D; Wechsler, Michael E; Simon, Hans-Uwe (2015). Novel targeted therapies for eosinophil-associated diseases and allergy. Annual review of pharmacology and toxicology, 55(1), pp. 633-656. Annual Reviews Inc. 10.1146/annurev-pharmtox-010814-124407

Text Novel targeted therapies for eosinophil-associated diseases and allergy.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB) | Request a copy

Eosinophil-associated diseases often present with life-threatening manifestations and/or chronic organ damage. Currently available therapeutic options are limited to a few drugs that often have to be prescribed on a lifelong basis to keep eosinophil counts under control. In the past 10 years, treatment options and outcomes in patients with clonal eosinophilic and other eosinophilic disorders have improved substantially. Several new targeted therapies have emerged, addressing different aspects of eosinophil expansion and inflammation. In this review, we discuss available and currently tested agents as well as new strategies and drug targets relevant to both primary and secondary eosinophilic diseases, including allergic disorders.

Interest & Impact

Downloads

13 since deposited on 24 Jul 2015
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item